$MYL Mylan N.V. (MYL) said Tuesday that the company and development partner Synthon, a treatment for multiple sclerosis, has won a significant European Patent Office ruling related to Copaxone 40 mg/mL. According to Mylan, the... https://t.co/Jyepf7rD9g

$MYL Mylan N.V. (MYL) said Tuesday that the company and development partner Synthon, a treatment for multiple sclerosis, has won a significant European Patent Office ruling related to Copaxone 40 mg/mL. According to Mylan, the... https://t.co/Jyepf7rD9g

— AllCEUs Counselor Education with Dawn-Elise Snipes (@All_CEUs) September 16, 2020

from Twitter https://twitter.com/All_CEUs

September 16, 2020 at 09:13AM
via IFTTT